A citation-based method for searching scientific literature

Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford, Richard Marais. Cell 2004
Times Cited: 2007







List of co-cited articles
786 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
38

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
21

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Zhan Yao, Neilawattie M Torres, Anthony Tao, Yijun Gao, Lusong Luo, Qi Li, Elisa de Stanchina, Omar Abdel-Wahab, David B Solit, Poulikos I Poulikakos,[...]. Cancer Cell 2015
257
19

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Zhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, Anthony Tao, Neilawattie M Torres, Matthew T Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough,[...]. Nature 2017
261
15

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikos I Poulikakos, Chao Zhang, Gideon Bollag, Kevan M Shokat, Neal Rosen. Nature 2010
14

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Sonja J Heidorn, Carla Milagre, Steven Whittaker, Arnaud Nourry, Ion Niculescu-Duvas, Nathalie Dhomen, Jahan Hussain, Jorge S Reis-Filho, Caroline J Springer, Catrin Pritchard,[...]. Cell 2010
13


RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Georgia Hatzivassiliou, Kyung Song, Ivana Yen, Barbara J Brandhuber, Daniel J Anderson, Ryan Alvarado, Mary J C Ludlam, David Stokoe, Susan L Gloor, Guy Vigers,[...]. Nature 2010
12

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
12

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
11

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
425
11

Regulation of RAF protein kinases in ERK signalling.
Hugo Lavoie, Marc Therrien. Nat Rev Mol Cell Biol 2015
341
10

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
James Tsai, John T Lee, Weiru Wang, Jiazhong Zhang, Hanna Cho, Shumeye Mamo, Ryan Bremer, Sam Gillette, Jun Kong, Nikolas K Haass,[...]. Proc Natl Acad Sci U S A 2008
960
10

The RAF proteins take centre stage.
Claudia Wellbrock, Maria Karasarides, Richard Marais. Nat Rev Mol Cell Biol 2004
849
10

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar,[...]. Nature 2010
10

Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T Flaherty, Igor Puzanov, Kevin B Kim, Antoni Ribas, Grant A McArthur, Jeffrey A Sosman, Peter J O'Dwyer, Richard J Lee, Joseph F Grippo, Keith Nolop,[...]. N Engl J Med 2010
10

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
10

Guilty as charged: B-RAF is a human oncogene.
Mathew J Garnett, Richard Marais. Cancer Cell 2004
603
9

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
9

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
473
9

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, Rene Gonzalez, Anna C Pavlick, Jeffrey S Weber, Grant A McArthur, Thomas E Hutson, Stergios J Moschos, Keith T Flaherty,[...]. N Engl J Med 2012
9

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Matthew Dankner, April A N Rose, Shivshankari Rajkumar, Peter M Siegel, Ian R Watson. Oncogene 2018
157
8

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
483
8

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Scott Kopetz, Jayesh Desai, Emily Chan, Joel Randolph Hecht, Peter J O'Dwyer, Dipen Maru, Van Morris, Filip Janku, Arvind Dasari, Woonbook Chung,[...]. J Clin Oncol 2015
399
8

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Mathew J Garnett, Sareena Rana, Hugh Paterson, David Barford, Richard Marais. Mol Cell 2005
304
8

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay,[...]. Nature 2011
8

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
444
8

BRAFV600E: implications for carcinogenesis and molecular therapy.
Emma R Cantwell-Dorris, John J O'Leary, Orla M Sheils. Mol Cancer Ther 2011
279
8

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets,[...]. Nature 2010
8

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L Beijersbergen, Alberto Bardelli, René Bernards. Nature 2012
8

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.
Zoi Karoulia, Yang Wu, Tamer A Ahmed, Qisheng Xin, Julien Bollard, Clemens Krepler, Xuewei Wu, Chao Zhang, Gideon Bollag, Meenhard Herlyn,[...]. Cancer Cell 2016
82
8

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Georgina V Long, Alexander M Menzies, Adnan M Nagrial, Lauren E Haydu, Anne L Hamilton, Graham J Mann, T Michael Hughes, John F Thompson, Richard A Scolyer, Richard F Kefford. J Clin Oncol 2011
746
7

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Zhan Yao, Yijun Gao, Wenjing Su, Rona Yaeger, Jessica Tao, Na Na, Ying Zhang, Chao Zhang, Andrey Rymar, Anthony Tao,[...]. Nat Med 2019
84
8

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
474
7

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev V Demidov, Jessica C Hassel, Piotr Rutkowski, Peter Mohr,[...]. N Engl J Med 2012
7

Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.
Eunyoung Park, Shaun Rawson, Kunhua Li, Byeong-Won Kim, Scott B Ficarro, Gonzalo Gonzalez-Del Pino, Humayun Sharif, Jarrod A Marto, Hyesung Jeon, Michael J Eck. Nature 2019
95
7

Vemurafenib: the first drug approved for BRAF-mutant cancer.
Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Keith Nolop, Peter Hirth. Nat Rev Drug Discov 2012
452
7

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
7

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, Erin M Coffee, Michiya Nishino, Alexandria P Cogdill, Ronald D Brown, Patricia Della Pelle, Dora Dias-Santagata, Kenneth E Hung,[...]. Cancer Discov 2012
646
7

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim,[...]. N Engl J Med 2012
7

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Ryan B Corcoran, Thierry André, Chloe E Atreya, Jan H M Schellens, Takayuki Yoshino, Johanna C Bendell, Antoine Hollebecque, Autumn J McRee, Salvatore Siena, Gary Middleton,[...]. Cancer Discov 2018
278
7

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Nikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, Dennie T Frederick, Zachary A Cooper, Amaro Taylor-Weiner, Mara Rosenberg, Eva M Goetz, Ryan J Sullivan, Deborah N Farlow,[...]. Cancer Discov 2014
340
7

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
7

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
6

Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
Jacob R Haling, Jawahar Sudhamsu, Ivana Yen, Steve Sideris, Wendy Sandoval, Wilson Phung, Brandon J Bravo, Anthony M Giannetti, Ariana Peck, Alexandre Masselot,[...]. Cancer Cell 2014
128
6

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Christian Menzer, Alexander M Menzies, Matteo S Carlino, Irene Reijers, Emma J Groen, Thomas Eigentler, Jan Willem B de Groot, Astrid A M van der Veldt, Douglas B Johnson, Frank Meiss,[...]. J Clin Oncol 2019
44
13

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
259
6

RAS isoforms and mutations in cancer at a glance.
G Aaron Hobbs, Channing J Der, Kent L Rossman. J Cell Sci 2016
414
6

Allosteric activation of functionally asymmetric RAF kinase dimers.
Jiancheng Hu, Edward C Stites, Haiyang Yu, Elizabeth A Germino, Hiruy S Meharena, Philip J S Stork, Alexandr P Kornev, Susan S Taylor, Andrey S Shaw. Cell 2013
182
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.